Clinical Trial Update: Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update evaluating Vaccination with 6MHP with or without CDX-1127 in patients with melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• 6MHP
• CDX-1127 (CDX-1127)

Snippet

Sponsor: Craig L Slingluff, Jr | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED